Bristol-Myers Delivers Positive Reblozyl Phase 2 Results

Bristol-Myers Squibb announced on February 23 positive top-line results from a Phase 2 registrational study of Reblozyl for anemia in adults with alpha-thalassemia outside the U.S., with both non‑transfusion-dependent and transfusion-dependent cohorts meeting primary endpoints and all key secondary endpoints. On February 25, RBC Capital initiated coverage with a Sector Perform rating and a $60 price target, citing a deep late-stage pipeline and balanced risk-reward.